Targeting a Tumor-Specific Epitope on Podocalyxin Increases Survival in Human Tumor Preclinical Models.

While we observed a trend toward tumor regression in mice treated with PODO447-ADC compared to control, this did not reach statistical significance likely due to half of the control-treated mice reaching their humane endpoint very early ( Figure 6B ).

also in 111,027 other papers